A modern healthcare system should invest in diagnostics and testing
March 5, 2021
Thierry Bernard, CEO of QIAGEN, says the COVID-19 pandemic might yet have an upside: more prevention-driven healthcare.
Modern testing has traditionally been undervalued and underestimated. While 66 percent of treatment decision-making was based on so-called in-vitro diagnostics, only 2.3 percent of US healthcare expenditure went into buying these regulated testing devices.
The world has taken its eye off tuberculosisTuberculosis is highly infectious and a global problem that Covid-19 has only made worse. Two legacies of the response to Covid-19 give rise to hope.
RNA, DNA and the rising cost of IP management (Or if too long: The rising cost of IP management)Advances in molecular testing are making patent protection and monitoring ever more difficult. It is time for the sector to reach for new tools.
Empower your careerMaking a lateral move to a different department or function can allow you to explore a new opportunity without having to start over completely.